Standard Biotools Financials
| LAB Stock | USD 1.54 0.26 20.31% |
Standard Biotools Balance Sheet Chart
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 4.26 | 6.56 |
|
|
The financial analysis of Standard Biotools is a critical element in measuring its lifeblood. Investors should not minimize Standard Biotools' ability to pay suppliers or employees on time, ensuring interest payments are not accumulating.
Cash And Equivalents |
|
Standard | Select Account or Indicator | Build AI portfolio with Standard Stock |
Please note, the presentation of Standard Biotools' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Standard Biotools' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Standard Biotools' management manipulating its earnings.
Standard Biotools Stock Summary
Standard Biotools competes with Varex Imaging, CeriBell, Cullinan Oncology, Avanos Medical, and So Young. Standard BioTools Inc. creates, manufactures, and markets instruments, consumables, reagents, and software for researchers and clinical laboratories worldwide. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California. Standard Biotools operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 615 people.Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | USA Stock View All |
| Exchange | NASDAQ Exchange |
| ISIN | US34385P1084 |
| Business Address | 2 Tower Place, |
| Sector | Life Sciences Tools & Services |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.standardbio.com |
| Phone | 650 266 6000 |
| Currency | USD - US Dollar |
Standard Biotools Key Financial Ratios
| Return On Equity | -0.33 | ||||
| Profit Margin | (0.76) % | ||||
| Operating Margin | (0.29) % | ||||
| Price To Sales | 2.90 X | ||||
| Revenue | 174.43 M |
Standard Biotools Key Balance Sheet Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 275.2M | 390.3M | 323.1M | 612.3M | 704.2M | 739.4M | |
| Other Current Liab | 12.2M | 14.2M | 18.7M | 27.2M | 31.3M | 32.9M | |
| Net Debt | 83.2M | 21.3M | 46.5M | (133.7M) | (153.8M) | (146.1M) | |
| Retained Earnings | (736.0M) | (926.1M) | (1.0B) | (1.2B) | (1.1B) | (1.0B) | |
| Accounts Payable | 10.6M | 7.9M | 9.2M | 12.3M | 14.1M | 14.8M | |
| Cash | 28.5M | 81.3M | 51.7M | 166.7M | 191.7M | 201.3M | |
| Net Receivables | 18.3M | 17.3M | 19.7M | 33.6M | 38.6M | 40.6M | |
| Inventory | 20.8M | 21.5M | 20.5M | 40.7M | 46.8M | 49.2M | |
| Other Current Assets | 4.5M | 4.3M | 3.1M | 8.7M | 10.0M | 10.5M | |
| Total Liab | 180.6M | 471.8M | 471.1M | 140.6M | 161.7M | 220.5M | |
| Total Current Assets | 72.1M | 208.8M | 158.2M | 375.9M | 432.3M | 453.9M | |
| Short Term Debt | 9.9M | 5.8M | 63.9M | 6.2M | 7.2M | 8.2M | |
| Common Stock | 77K | 80K | 83K | 396K | 455.4K | 478.2K | |
| Intangible Assets | 27.9M | 12.6M | 1.4M | 29.0M | 26.1M | 37.5M | |
| Good Will | 106.4M | 106.3M | 106.3M | 111.3M | 128.0M | 116.1M | |
| Other Assets | 2.6M | 2.7M | 2.4M | 3.1M | 2.8M | 3.4M | |
| Long Term Debt | 64.2M | 62.8M | 4.0M | 299K | 269.1K | 255.6K | |
| Long Term Debt Total | 53.8M | 54.2M | 64.2M | 62.8M | 56.5M | 91.1M | |
| Capital Surpluse | 777.8M | 815.6M | 831.4M | 847.0M | 974.1M | 774.5M | |
| Cash And Equivalents | 5.0M | 20.7M | 28.5M | 81.3M | 93.5M | 98.2M | |
| Other Liab | 20.2M | 39.1M | 29.3M | 20.2M | 23.2M | 28.7M | |
| Net Tangible Assets | 372K | (9.7M) | (41.0M) | 110.9M | 127.6M | 134.0M | |
| Net Invested Capital | 165.6M | (16.6M) | (84.5M) | 472.0M | 424.8M | 446.1M | |
| Capital Stock | 77K | (81.5M) | 83K | 396K | 356.4K | 374.2K |
Standard Biotools Key Income Statement Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Interest Expense | 3.8M | 4.3M | 4.6M | 3.3M | 3.8M | 4.4M | |
| Total Revenue | 130.6M | 97.9M | 106.3M | 174.4M | 200.6M | 210.6M | |
| Gross Profit | 77.3M | 37.1M | 50.5M | 84.3M | 96.9M | 50.9M | |
| Operating Income | (67.5M) | (116.2M) | (76.6M) | (175.2M) | (157.7M) | (149.8M) | |
| Ebit | (67.5M) | (188.6M) | (69.6M) | (135.0M) | (121.5M) | (115.4M) | |
| Research Development | 37.9M | 37.4M | 25.9M | 62.4M | 71.8M | 75.4M | |
| Ebitda | (44.3M) | (173.6M) | (54.5M) | (118.1M) | (106.3M) | (101.0M) | |
| Cost Of Revenue | 53.3M | 60.9M | 55.9M | 90.2M | 103.7M | 108.9M | |
| Income Before Tax | (63.7M) | (192.9M) | (74.2M) | (138.3M) | (124.5M) | (118.3M) | |
| Net Income | (59.2M) | (190.1M) | (74.7M) | (138.9M) | (125.0M) | (118.7M) | |
| Income Tax Expense | (4.4M) | (2.8M) | 452K | 573K | 515.7K | 541.5K | |
| Tax Provision | (4.4M) | (2.8M) | 684K | 573K | 659.0K | 691.9K | |
| Interest Income | 3.8M | 64.4M | 5.6M | 20.2M | 23.2M | 15.6M | |
| Net Interest Income | (3.8M) | (4.3M) | (4.7M) | 16.9M | 19.4M | 20.4M |
Standard Biotools Key Cash Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Change To Inventory | (4.8M) | (8.5M) | (4.9M) | (9.9M) | (8.9M) | (8.4M) | |
| Change In Cash | (40.1M) | 52.9M | (29.8M) | 116.3M | 133.8M | 140.5M | |
| Free Cash Flow | (57.3M) | (93.2M) | (46.1M) | (151.8M) | (136.6M) | (129.8M) | |
| Depreciation | 16.2M | 15.0M | 15.2M | 16.9M | 19.4M | 10.7M | |
| Other Non Cash Items | 886K | 83.2M | 1.3M | (41.1M) | (47.2M) | (44.9M) | |
| Capital Expenditures | 13.3M | 3.8M | 2.8M | 8.4M | 9.6M | 4.9M | |
| Net Income | (59.2M) | (190.1M) | (74.7M) | (138.9M) | (125.0M) | (118.7M) | |
| End Period Cash Flow | 29.5M | 82.3M | 52.5M | 168.8M | 194.1M | 203.8M | |
| Investments | (11.9M) | (88.1M) | 73.6M | 363.2M | 417.7M | 438.5M | |
| Change To Netincome | 25.4M | 16.7M | 18.4M | 30.7M | 35.3M | 22.8M |
Standard Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Standard Biotools's current stock value. Our valuation model uses many indicators to compare Standard Biotools value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Standard Biotools competition to find correlations between indicators driving Standard Biotools's intrinsic value. More Info.Standard Biotools is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . At present, Standard Biotools' Return On Equity is projected to increase slightly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Standard Biotools' earnings, one of the primary drivers of an investment's value.Most indicators from Standard Biotools' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Standard Biotools current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Standard Biotools. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Standard Stock refer to our How to Trade Standard Stock guide.The current year's Tax Provision is expected to grow to about 691.9 K, whereas Selling General Administrative is forecasted to decline to about 110.5 M.
| 2023 | 2024 | 2025 | 2026 (projected) | Interest Expense | 4.6M | 3.3M | 3.8M | 4.4M | Depreciation And Amortization | 15.2M | 16.9M | 19.4M | 10.9M |
Standard Biotools fundamental ratios Correlations
Click cells to compare fundamentals
Standard Biotools Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Standard Biotools fundamental ratios Accounts
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Total Assets | 275.2M | 390.3M | 323.1M | 612.3M | 704.2M | 739.4M | |
| Other Current Liab | 12.2M | 14.2M | 18.7M | 27.2M | 31.3M | 32.9M | |
| Net Debt | 83.2M | 21.3M | 46.5M | (133.7M) | (153.8M) | (146.1M) | |
| Retained Earnings | (736.0M) | (926.1M) | (1.0B) | (1.2B) | (1.1B) | (1.0B) | |
| Accounts Payable | 10.6M | 7.9M | 9.2M | 12.3M | 14.1M | 14.8M | |
| Cash | 28.5M | 81.3M | 51.7M | 166.7M | 191.7M | 201.3M | |
| Net Receivables | 18.3M | 17.3M | 19.7M | 33.6M | 38.6M | 40.6M | |
| Inventory | 20.8M | 21.5M | 20.5M | 40.7M | 46.8M | 49.2M | |
| Other Current Assets | 4.5M | 4.3M | 3.1M | 8.7M | 10.0M | 10.5M | |
| Total Liab | 180.6M | 471.8M | 471.1M | 140.6M | 161.7M | 220.5M | |
| Total Current Assets | 72.1M | 208.8M | 158.2M | 375.9M | 432.3M | 453.9M | |
| Short Term Debt | 9.9M | 5.8M | 63.9M | 6.2M | 7.2M | 8.2M | |
| Common Stock | 77K | 80K | 83K | 396K | 455.4K | 478.2K | |
| Intangible Assets | 27.9M | 12.6M | 1.4M | 29.0M | 26.1M | 37.5M | |
| Good Will | 106.4M | 106.3M | 106.3M | 111.3M | 128.0M | 116.1M | |
| Other Assets | 2.6M | 2.7M | 2.4M | 3.1M | 2.8M | 3.4M | |
| Long Term Debt | 64.2M | 62.8M | 4.0M | 299K | 269.1K | 255.6K | |
| Long Term Debt Total | 53.8M | 54.2M | 64.2M | 62.8M | 56.5M | 91.1M | |
| Capital Surpluse | 777.8M | 815.6M | 831.4M | 847.0M | 974.1M | 774.5M | |
| Cash And Equivalents | 5.0M | 20.7M | 28.5M | 81.3M | 93.5M | 98.2M | |
| Other Liab | 20.2M | 39.1M | 29.3M | 20.2M | 23.2M | 28.7M | |
| Net Tangible Assets | 372K | (9.7M) | (41.0M) | 110.9M | 127.6M | 134.0M | |
| Net Invested Capital | 165.6M | (16.6M) | (84.5M) | 472.0M | 424.8M | 446.1M | |
| Capital Stock | 77K | (81.5M) | 83K | 396K | 356.4K | 374.2K |
Today, most investors in Standard Biotools Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Standard Biotools' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Standard Biotools growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Standard Biotools January 9, 2026 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Standard Biotools help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Standard Biotools. We use our internally-developed statistical techniques to arrive at the intrinsic value of Standard Biotools based on widely used predictive technical indicators. In general, we focus on analyzing Standard Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Standard Biotools's daily price indicators and compare them against related drivers.
| Downside Deviation | 4.6 | |||
| Information Ratio | 0.0549 | |||
| Maximum Drawdown | 18.53 | |||
| Value At Risk | (7.04) | |||
| Potential Upside | 6.87 |
Complementary Tools for Standard Stock analysis
When running Standard Biotools' price analysis, check to measure Standard Biotools' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Standard Biotools is operating at the current time. Most of Standard Biotools' value examination focuses on studying past and present price action to predict the probability of Standard Biotools' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Standard Biotools' price. Additionally, you may evaluate how the addition of Standard Biotools to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |